Quality Control 111.105: Meaning, Evidence and Controls

quality control 111.105 means the responsibilities assigned to quality control personnel for ensuring quality in US dietary supplement manufacturing, packaging, labeling and holding under 21 CFR 111.105.

For US dietary supplements, that introductory paragraph also assigns QC personnel responsibility for ensuring that the supplement is packaged and labeled as specified in the master manufacturing record. The subject is therefore broader than laboratory testing: it concerns quality across the named operations, including conformity to the manufacturing instructions for packaging and labeling.

In practical manufacturing workflows, laboratory results are evidence used in decisions, not substitutes for the decisions themselves. A useful starting question is not simply whether a test passed, but what decision the evidence supports and who is responsible for making it. This keeps an analytical result from being mistaken for an operational approval.

This article uses distinct action terms: preparing evidence, reviewing evidence, approving an activity, deciding a material’s disposition and deciding a batch’s status. These are practical distinctions for organizing work, not competing legal definitions. The sections below develop each at its relevant decision point within 21 CFR Part 111, so that a completed task, an evidence review and an authorized decision remain distinguishable.

This article’s regulatory analysis is limited to US dietary supplements under 21 CFR Part 111. Similar quality titles are not interchangeable sources of authority. Other products and jurisdictions need their own applicability assessment; a shared department name does not establish shared regulatory responsibilities.

How to read the controls

• Binding rules: the US dietary supplement provisions discussed here are identified by their Part 111 citations.
• Official guidance: a separate category from law, not an interchangeable label for a binding provision.
• Practical recommendations: suggested ways to organize work and evidence, not additional regulatory obligations.
• Software support: tools can support a workflow; they are not legal authority.

Use this terminology map for navigation, not to transfer department structures, independence assumptions or decision rights between frameworks.

For US dietary supplements, 21 CFR 111.12(b) requires identification of the people responsible for QC operations and qualification of each person assigned those operations. Under that same provision, for US dietary supplements, their QC responsibilities must be distinct and separate from their responsibilities when not performing QC operations. For US dietary supplements, 21 CFR 111.12(c) requires education, training or experience appropriate to each person’s assigned functions.

For practical role design, evaluate whether a single qualified person can cover the applicable QC duties where law permits; do not default to a universal independent department or minimum headcount. Assess competence, workload, competing duties and absence coverage. Preparing a supplier dossier, compiling results or assembling a batch record is not the same task as making the specified QC decision.

Use an illustrative responsibility matrix to make those boundaries visible; replace role labels with named personnel:

Connect assignments to a training record and an operator skill matrix. As a practical coverage check, identify who handles urgent decisions during absence and which work waits if no qualified alternate is available. A preparer’s completion status should not be mistaken for the QC owner’s decision.

For US dietary supplements, 21 CFR 111.103 requires established and followed written procedures for QC responsibilities, including material review, disposition decisions and approval or rejection of reprocessing. For US dietary supplements, 21 CFR 111.105(a) assigns QC approval or rejection of all processes, specifications, written procedures, controls, tests, examinations, and deviations or modifications that may affect identity, purity, strength or composition.

A practical lifecycle map connects that authority to identifiable decision objects. The sequence below is an organizing model, not a prescribed workflow or mandatory software configuration. Detailed receiving, laboratory, exception and batch duties belong at their respective decision gates.

For example, assume a proposed revision to a component specification changes its referenced test method while received material remains under evaluation. A practical change review identifies the existing and proposed versions, the affected lots and tests, and the responsible QC reviewer before changing any record's status. It also identifies whether related master manufacturing records or open batch records reference the superseded criteria.

Record the reviewer's decision about which work uses which version and whether existing results need further evaluation. Avoid replacing the method reference on completed work merely because a newer version exists: that would obscure what actually governed the test. A useful handoff carries the decision, its scope and its supporting record together, rather than passing only an approved status. This keeps the change decision distinct from subsequent decisions about individual lots or batches.

For US dietary supplements, 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of a dietary-ingredient component before use, unless FDA grants the exemption requested by petition under that provision. Supplier approval itself does not grant that exemption. Keep component identity confirmation separate from the supplier’s qualification status: they answer different questions.

For components that are not dietary ingredients, 21 CFR 111.75(a)(2) requires confirming identity before use and determining whether other applicable component specifications are met. That can be done by appropriate tests or examinations, or by relying on a supplier certificate of analysis only where the stated conditions are satisfied. Identity confirmation and compliance with other component specifications are separate determinations; the certificate route can support either only within those conditions. Do not replace that with a blanket rule that every component receives identical identity testing on every receipt.

For US dietary supplements, the conditional supplier-certificate route under 21 CFR 111.75(a)(2)(ii)(A)–(E) requires the following where that route applies; it is not a substitute for the dietary-ingredient identity obligation above:

• First qualify the supplier by establishing certificate reliability through confirmation of the supplier’s test or examination results.
• Ensure the certificate describes the methods used, test or examination limits, and actual results.
• Maintain documentation showing how the supplier was qualified.
• Periodically reconfirm the supplier’s certificate of analysis.
• Have QC personnel review and approve the documentation establishing the basis for supplier qualification and requalification.

A practical supplier CoA verification programme keeps these supporting records distinguishable from the certificate received with a particular lot.

For US dietary supplements, 21 CFR 111.120(a), (b) and (e) assigns QC review of all receiving records, determination of conformity to established specifications, and approval and release from quarantine before components, packaging and labels are used.

Worked receiving case

Assumptions: the incoming material is a dietary ingredient intended for US supplement manufacture; no FDA-granted exemption applies. Unit of analysis: component lot. The supplier is approved and a certificate accompanies the lot, but its identity evidence remains unresolved. This illustrative workflow separates evidence collection from the readiness-for-use decision.

For US dietary supplements, 21 CFR 111.110(a)–(c) assigns QC review and approval of laboratory control processes, responsibility for ensuring that tests and examinations required under 111.75 are conducted, and review and approval of their results. These are distinct responsibilities: approving a laboratory process does not replace reviewing its results.

For US dietary supplements, 21 CFR 111.105(c) assigns QC review and approval of the documented basis explaining why meeting in-process specifications, together with component specifications, will help ensure supplement identity, purity, strength and composition. This rationale explains the relationship between controls; an individual analytical result records what a particular test found.

For US dietary supplements, 21 CFR 111.75(c)(4) and (d)(2) require QC review and approval of the documentation identified in (c)(3) and (d)(1), respectively. Under these provisions for US dietary supplements, finished-batch verification documentation explains why selected testing establishes compliance with all product specifications; exemption documentation explains why an exempted specification will be met without periodic finished-batch testing. Check the current text of (c) and (d) for the complete conditions; these are different rationales, not interchangeable approval records.

For US dietary supplements, 21 CFR 111.105(f) and (g) assign QC responsibility for ensuring collection of required representative samples and collection and holding of required reserve samples. Keep the reserve sample program connected to the relevant material or batch.

As a practical traceability design—not a prescribed database structure—connect specification version → method → sample → result → interpretation → QC decision. Use document control to preserve the applicable specification version. For example, assume an acceptable result is attached to a neighboring lot’s record, or interpreted against a superseded specification. The analytical value alone cannot resolve either mismatch. A reviewer can trace sample identity, confirm the applicable method and specification, then document the interpretation supporting the decision. This separates technical acceptability from evidence that the result actually supports the decision for that lot.

For the reviews identified above, link each decision to its supporting evidence. This matrix is a practical record design, not an exhaustive legal record checklist or prescribed database schema.

The current master document describes the presently controlled instructions; an executed batch record points to the version associated with that batch. A later revision does not rewrite that history. A recipe supersession log can connect revisions. Preserve the reviewed record’s identity and version, reviewer, decision, decision time, supporting evidence and later corrections without obscuring the original entry.

Data-model diagram: these entities are records that can exist on paper, in controlled files or in configured systems. Arrows describe relationships, not automated approvals.

Component lot → consumption record → batch Master version → executed batch record Exception → affected lots, results or batches QC decision → precise reviewed object/version + supporting evidence Reviewer identity → QC decision

For example, assume a batch has an approved status. Begin with that decision and trace backward to its applicable master record, component and packaging decisions, laboratory results and exception dispositions. Check that each link identifies the evidence actually reviewed, rather than a subsequently replaced file. An uploaded attachment or populated status field alone does not demonstrate completed substantive review; reconstruct who decided what, on which evidence, and when.

For US dietary supplements, 21 CFR 111.113(a) requires QC personnel to conduct a material review and make a disposition decision for the following triggers.

For US dietary supplements with a specification failure, 21 CFR 111.113(b)(2) requires QC rejection of the component, supplement, package or label unless QC approves treatment, an in-process adjustment or reprocessing as permitted in § 111.77; check the current text of § 111.77 for that permission’s scope.

For US dietary supplement production and in-process controls, 21 CFR 111.113(b)(1) requires rejection when a deviation or unanticipated occurrence results in or could lead to adulteration, or could lead to an unspecified label, unless QC approves treatment, adjustment or reprocessing to correct it.

Worked case: calibration finding with unresolved batch impact

Assume the instrument supported recorded batch measurements, the affected production scope is initially unresolved, and no disposition has been made. Units of analysis are the instrument record, measurement record and affected batch. The following is an illustrative practice sequence, not a prescribed technical assessment method.

1. Identify the instrument and preserve the calibration finding, equipment history and measurement references.
2. Trace potentially affected work through instrument-use and batch records. Keep uncertain associations visible rather than assuming unlinked work was unaffected.
3. Assess the evidence: which recorded measurements depended on the instrument, what decisions used them, and whether available information resolves their reliability. Connect any identified specification failure to the out-of-specification handling record.
4. Present the impact assessment and unresolved questions for QC disposition. Distinguish proposed corrective work from work QC has authorized.
5. Record any authorized corrective work and its resulting evidence. Keep instrument restoration separate from resolution of earlier batch impact: a satisfactory calibration after repair does not establish that earlier measurements were reliable.

For US dietary supplements, 21 CFR 111.123(a)(1)–(3) assigns QC review and approval of all master manufacturing records and modifications, review and approval of all batch production-related records, and review of all monitoring required under subpart E. An acceptable laboratory report does not replace these reviews.

For US dietary supplements, 21 CFR 111.123(a)(4), (5) and (8) distinguishes required material review and disposition, approval or rejection of reprocessing, and approval and release—or rejection—of each finished batch for distribution, including reprocessed batches. These are separate decisions, not interchangeable approval labels.

For US dietary supplements, 21 CFR 111.123(b)(1)–(4) prohibits QC approval and release for distribution of:

• A batch containing any component that fails its identity specification.
• A batch, including a reprocessed batch, that fails any product specification established under § 111.70(e).
• A batch, including a reprocessed batch, not manufactured, packaged, labeled and held under the specified adulteration-prevention conditions.
• Supplier-received product intended for packaging or labeling as a dietary supplement and distribution—not return to the supplier—without sufficient assurance of product identification and consistency with the purchase order.

Worked case: acceptable results, incomplete execution

Assumptions: reported laboratory results are acceptable; a master-record step was genuinely omitted, not merely left unsigned; the omission is confirmed; the batch has not been distributed. Unit of analysis: batch.

1. Apply the material-review process covered above. Identify the omitted operation and assess its effect; do not treat acceptable results as evidence that the operation occurred.
2. Distinguish any authorized corrective action from its execution. Authorization alone does not demonstrate completion, and this example assumes no permissible recovery outcome.
3. If recovery is authorized, document execution and supporting evidence in the batch record, then return the record for the batch decision.

In this practical sequence, closing the exception records completion of exception handling; it is not itself batch release. QC personnel make the decision; a workflow status does not release autonomously.

Workflow: Record review → Exception pathway, if needed → Execution evidence → QC batch decision → Release or rejection.

For US dietary supplements, 21 CFR 111.117(a)–(c) requires QC review and approval of all instrument and control calibration processes, plus periodic review of all calibration records for instruments and controls and all calibration, inspection and check records for automated, mechanical or electronic equipment. For US dietary supplements, 21 CFR 111.117(d) also requires QC review and approval of controls to ensure that automated, mechanical or electronic equipment functions according to its intended use.

For US dietary supplements, 21 CFR 111.75(g) requires, at minimum, visual examination of finished-product packaging and labeling to determine whether the specified packaging and label were used. This is a physical packaging and labeling check, not merely confirmation that an electronic record names the intended materials.

As optional implementation practice, receiving, laboratory, production and quality record handoffs should preserve identifiers, versions and supporting attachments. Useful data integrity controls flag mismatched identifiers, stale versions, duplicate messages, missing attachments and interrupted transfers. After an interruption, reconcile source and destination records, confirm attachment access, and distinguish successfully transferred records from pending or duplicated records before resuming the affected decision workflow. Assign an owner to resolve discrepancies and record the reconciliation outcome; a successful retransmission alone does not establish that the decision evidence is complete.

Use these practical self-assessment prompts alongside the earlier personnel, component, laboratory and batch-decision sections. They test whether evidence supports a decision, rather than adding regulatory requirements or ranking inspection findings.

• Identify the QC decision owner and locate qualification evidence applicable to the assigned work.
• Distinguish who prepared the evidence from who reviewed and approved it.
• Retrieve the specification and master-record versions applicable to the executed work.
• Trace incoming-material decisions through lot pedigree to the batch.
• Locate result-review evidence, not merely the analytical report.
• Connect exceptions to affected materials, equipment, operations and batches.
• Separate material disposition and reprocessing decisions from the finished-batch decision.

Finish with a backward trace exercise: start at a finished-batch decision and reconstruct its supporting people, materials, results, document versions and exception decisions through the batch execution history. Ask a reviewer unfamiliar with the batch to follow that chain. Record unresolved links for follow-up. The useful outcome is an explainable decision chain, not merely a complete-looking folder.